Meridian Bioscience, Inc. Comments on Preliminary Fiscal 2017 Operating Results and Provides Fiscal 2018 Revenue and Earnings Guidance
CINCINNATI, Oct. 19, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that based on preliminary results, it expects revenues for fiscal 2017, ended on September 30, 2017, to be approximately $200.5 million, an increase of 2% compared to the prior year. Diluted earnings per share on a GAAP basis are expected to be […]